Although safe, paracetamol, commonly used in children, can cause adverse events if not administered correctly. This research aimed to investigate caregivers' knowledge about children's paracetamol. A convenience sample of caregivers who had purchased Children's Panadol were asked to complete an online survey, assessing their knowledge of paracetamol. Most of the 174 respondents were female (93.7%), highly-educated (72.4%) with adequate functional health literacy (85.6%). Almost all respondents correctly identified that Children's Panadol contained paracetamol (96.6%). However, approximately a quarter of them did not know the maximum daily dose (26.4%), just under half (46%) did not know how many days this dose could be safely given, and over one-third (37.4%) did not know that liver toxicity could result from overdose. These findings suggest that adult caregivers administering paracetamol to children have gaps in their knowledge. Strategies to help improve caregiver's knowledge about the correct and safe administration of children's paracetamol need to be considered.
INTRODUCTION
Paracetamol, or acetaminophen, a medication commonly used to treat pain and fever, is readily available worldwide. 1 Over-the-counter (OTC) liquid preparations of paracetamol are frequently used in children, especially among those aged up to 2 years. 2 If given in accordance with dosage recommendations, paracetamol is safe and effective. 3 However, if given in doses that exceed these recommendations, paracetamol can cause severe adverse effects. 4 Notably, paracetamol is one of the most common agents of unintentional poisoning in young children [5] [6] [7] [8] and is a major cause of paediatric acute liver failure. 5, 9 Information about the safe administration of OTC paracetamol products can be obtained from health professionals, product packaging and information inserts. The aim of the present study was to investigate whether Australian adult caregivers have sufficient knowledge to correctly and safely administer paracetamol to children. The Children's Panadol brand was specifically chosen because it is a well-known and commonly purchased brand.
METHODS
Following Human Research Ethics approval from the University of Wollongong (HE14/455), a cross-sectional online survey was administered via SurveyMonkey between September and October 2015. The survey included demographic questions (seven items including a single health literacy screener item 10, 11 and questions regarding product knowledge required to safely and correctly administer children's paracetamol consisting of 12 items based on information available on the product packaging; see Appendix 1). To be able to answer Questions 12 and 13 of the survey, participants were provided with a copy of the dosage information provided on the packaging of Panadol Children 5-12 years. A convenience sample of respondents was obtained using Facebook. A link to the online survey (Appendix 1) was posted via Facebook to all Facebook friends of the research team. This was then followed by a snowball sampling technique, whereby study participants recruited via Facebook were encouraged to share the link to the survey with their Facebook friends. A link to the survey was also included on three Australian online parenting forums, namely Raising Children (http://raisingchildren.net.au/), BubHub (http:// www.bubhub.com.au/index.php) and Essential Baby (http://www.essentialbaby.com.au/).
Potential participants were informed that to be eligible to complete the survey they needed to have purchased one of the following products: Panadol Children 1 month-2 years, Panadol Children 1-5 years and/or Panadol Children 5-12 years.
Collected survey data were analysed using SPSS v.21 (IBM Corp., Armonk, NY, USA).
RESULTS

Respondent Demographics
The 174 respondents were mainly female (n = 163; 93.7%), aged between 21 and 68 years (mean (AESD) age 35.6 AE 6.7 years). Most were Australian born (n = 146; 83.9%) and tertiary educated (n = 126; 72.4%), with adequate functional health literacy scores (n = 149; 85.6%). The following is a breakdown of the Panadol products purchased by the respondents, some of whom had bought more than one product: Panadol Children 1 month-2 years (n = 64; 36.8%), Panadol Children 1-5 years (n = 74; 42.5%) and Panadol Children 5-12 years (n = 71; 40.8%). The respondents' children (who had received the Children's Panadol) were between 1 month and 12.6 years of age (mean age 5 years). The main reasons for administering Children's Panadol, which was mostly purchased from pharmacies (n = 172, 98.9%), were fever (n = 130; 74.7%) and pain (n = 95; 53.4%).
Knowledge About Children's Panadol
Active Ingredient
Almost all respondents knew that Children's Panadol contained paracetamol (n = 168; 96.6%). However, some also believed that the product contained alcohol (n = 36; 20.7%), aspirin (n = 24; 13.7%), codeine (n = 23; 13.2%) and/or ibuprofen (n = 18; 10.4%).
Contraindications and Potential Side Effects
Respondents' knowledge of contraindications and side effects was variable (Table 1 ). Prior to administering the children's paracetamol, most respondents (83.3%) knew to check with their doctor or pharmacist if their child was taking other medications. Notably, however, less than one-third (30.5%) knew that they did not need to check with their doctor or pharmacist if their child had asthma. The respondents' knowledge about allergies to other medications (e.g. ibuprofen, aspirin) or food products (e.g. milk, eggs, gluten) not being a contraindication to paracetamol administration was variable, with less knowledge about food products (47.7%-57.5%) than medications (64.4-74.1%; Table 1 ).
Respondents' knowledge of the potential side effects caused by paracetamol overdosing was low (Table 1) . Although just over 60% of respondents knew that liver toxicity was a potential side effect, approximately onefifth (21.3%) were unsure of any potential side effects associated with giving too much paracetamol.
Reading and Comprehending Dosage Instructions
After being provided with information from a Panadol Children 5-12 years packet, participants were asked to identify the correct dosage if their child: (1) was 9 years old; and (2) weighed 21 kg. Most respondents correctly interpreted recommended dosage instructions for both scenarios (n = 167 (96%) and n = 150 (86.2%), respectively). However, approximately one-quarter of the respondents (n = 40; 23.0%) did not know that a 4-h interval was required between doses, and a similar proportion of respondents (n = 46; 26.4%) did not know that four doses is the maximum number a child should receive within a 24-h period. Furthermore, just under half the respondents incorrectly believed that Children's Panadol could be safely given (without medical advice) for more than 2 days in a row (n = 80; 46%), with over one-third incorrectly believing that paracetamol could be safely administered to children for up to 1 week (n = 73; 42%).
DISCUSSION
The findings from the present study show gaps in respondents' knowledge regarding the safe administration of paracetamol to children, despite being a highly educated sample with high functional health literacy. For example, although the majority knew that paracetamol was the active ingredient in Children's Panadol, many believed that the product contained other active ingredients and that food allergies were contraindications for the administration of paracetamol to children. This may inadvertently result in children not receiving paracetamol when it is a safe option for the treatment of fever and pain, as was the case for many children included in the present study. In addition, approximately one-quarter of respondents were not aware of the correct interval between doses and did not recognise that four doses is the maximum a child should receive in a day. This lack of knowledge may lead to accidental overdosing of the child in their care. What is even more concerning is that almost 40% of respondents did not know that liver toxicity is a potential side effect associated with paracetamol overdose. These results are similar to those of other studies that investigated adults' knowledge about paracetamol doses and toxicity. 12, 13 Therefore, it could be argued that even though the majority of respondents in the present study purchased their Children's Panadol from a pharmacy (where they presumably received information about the product), further strategies are required to supplement this information channel and address their knowledge gaps. These strategies need to be considered by pharmacists working in both community and hospital settings, and could include improved pharmacist-consumer communication, as well as improved general knowledge about the safe administration of paracetamol and potential adverse events associated with overdose.
The present study has a number of limitations, which include the use of a self-report survey, possibly introducing reporting bias. The sample was relatively small and not reflective of the wider population because it was highly educated (86.2% of the sample had a trade or university qualification vs 43.6% of the population as a whole 14 ) and most respondents were born in Australia (83.9% in the sample vs 72.3% for Australia as a whole 15 ).
This may affect the generalisability of the results to the wider Australian population. However, it is important to consider the consequences of paracetamol administration to children by adult caregivers who are less educated with low functional health literacy, or are not fluent in English, because they may be experiencing even bigger gaps in their knowledge about the safe use and administration of paracetamol to the children in their care.
CONCLUSION
Despite the study having a highly educated sample, the findings suggest caregivers administering children's paracetamol have gaps in their product knowledge. This is an important public health concern given the ready access to OTC paracetamol products for children. To address these knowledge gaps, it is important to consider multiple strategies, which could include improving pharmacist-consumer communication and general knowledge about paracetamol and potential adverse events associated with overdose.
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